Abstract
INTRODUCTION
Rectal squamous cell carcinoma (SCC) is a rare malignancy of the gastrointestinal (GI) tract. Due to the low incidence of this cancer and subsequent lack of literature, the underlying pathogenesis and risk factors are yet to be clearly defined. Furthermore, there is significant heterogeneity in the treatment regimens utilised, with the optimal management yet to be clarified. Nonetheless, certain patterns do emerge on reviewing all published cases by way of a systematic review, to determine where our future research should be directed in order to improve upon treatment and facilitate best patient outcomes.
MATERIALS AND METHODS
A systematic literature review was conducted according to the preferred reporting items for Systematic Reviews and Meta-Analyses guidelines. A comprehensive search of Ovid Medline was performed with the abstracts screened to determine relevant articles, following which the full texts were obtained. A directed manual review of all embedded references was undertaken of the selected articles to ensure all studies published on primary SCC of the rectum were identified.
The search strategy was based on a combination of medical subject heading terms (carcinoma, squamous cell; rectum) and text words (SCC and rectum), spanning from 1946 to May 2015. The search was limited to English language with the most recent search performed on 8 th May 2015.
Inclusion and exclusion criteria
The definition of rectal SCC as stipulated by Williams et al [1] which requires three exclusion criteria to be met (detailed in "diagnosis" below) was used to identify relevant studies. Consequently, studies reporting rectal SCC arising in the presence of a fistula, from an anal or gynaecological origin, a distant site via metastasis, or where the pathology was mixed (e.g., adenosquamous) were excluded. Additionally, studies where the lesion was premalignant (e.g., metaplasia or SCC in situ), of colonic rather than rectal origin or where the data was inadequate were excluded from the quantitative analysis.
Data extraction
Data extracted included the names of the authors, date of publication, demographic information and clinical presentation. Location of the lesion and treatment detailing the primary modality, the use of pre-and/or post-operative modalities and the type of operation where present was also noted. Other collated information included patient outcomes in the form of local recurrence, metastasis, and survival, as well as the length of follow up. Radiological, clinical and pathological complete response (CR) was also recorded where available.
RESULTS
The database and bibliography search identified 487 articles in total. After screening the articles for inclusion and exclusion criteria, 79 were included in the qualitative review and 63 in the quantitative analysis as detailed in Figure 1 . This included 43 case reports and 20 case series with a total of 142 individual cases reported. Given the inherent bias in case reports and the inconsistency with reporting important prognostic variables including stage and pathological grade, an in depth individual patient data meta-analysis was not performed.
DISCUSSION

Background
Epidemiology: Rectal SCC is a rare disease with the current literature consisting primarily of case reports, case series and one large population based study.
While SCC can occur throughout the GI tract, it most commonly affects the upper aerodigestive tract down to the oesophagogastric junction, and the anal canal. SCC of the rectum however is much less common accounting for 0.3% of all histological subtypes [2] . While pure SCC is the most frequent histology, cases with a mixed histologic pattern, generally adenosquamous, have been described [3] . While other rectal cancer subtypes including neuroendocrine, lymphoma and gastrointestinal stromal tumours occur infrequently, rectal SCC remains the most rare with the exception of sarcoma [2] . Schmidtmann [4] reported the first case of SCC of the colon in 1919, with Raiford [5] publishing on the first case of rectal SCC in 1933. While SCC can be diagnosed throughout the colorectum, the most common site of predilection is the rectum (93.4%), followed by the right colon (3.4%) [2] . The true incidence of rectal SCC can be most accurately drawn from the large population based study from the National Cancer Institute (NCI), which estimated it at 1.9 per million population in the year 2000, or 3 per 1000 colorectal cancers. This study also identified a significant rise in the incidence of rectal SCC between 1992 and 2000, estimating it at 5.9% per year. Extrapolating from this figure, the current incidence may be as high as 3.5 per million population [2] . While strong epidemiological evidence on rectal SCC is absent, patient demographics and risk factors can be gauged from the published retrospective reviews and population study. Patients diagnosed with SCC of the rectum have ranged in age from 39 to 93 years old, with an average age of 63 years. Female gender predominates, accounting for 57.4% vs 42.6% of cases in the NCI study. Patients most frequently present with early stage localised (stage I/II, 52.8%) or regional (stage III, 29.3%) disease and there is no apparent ethnic or geographic predisposition [2] . Despite a lack of firm risk factors with a causal link to the development of rectal SCC, loose associations have been identified. The strongest association evident in the literature is that of proctitis, generally secondary to ulcerative colitis. There have been multiple case reports of rectal SCC in this setting, one of which compared the incidence with that of the general population to demonstrate a markedly increased risk in ulcerative colitis patients [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Of significance, there has also been a report of rectal SCC in the setting of active Crohn's disease of the rectum [16] , and in the setting of chronic prolapse [17] . Drawing upon this association with inflammation, the literature also contains three reports of parasitic infections with colorectal SCC, in the form of Schistosomiasis in two cases, and Amoebiasis in one, however, their significance is unclear [1, 18, 19] . Other postulated risk factors have included a past history of radiotherapy for other pelvic malignancies, which has been noted in several case reports [20] [21] [22] [23] . Additionally, colorectal adenocarcinoma, both synchronous and metachronous has been identified in patients with SCC of the rectum [3, [24] [25] [26] [27] . For colonic SCC, asbestos exposure and colonic duplication have also been associated, but this has not been the case for SCC of rectal origin. pluripotent mucosal stem cells capable of multidirectional differentiation, first postulated in the 1950's [17, [39] [40] [41] . Further work by Nahas et al [16] in 2007 was based on the fact that keratin profiles vary amongst epithelia but remain constant in neoplastic transformation. They demonstrated that rectal SCC and adenocarcinoma stain for cytokeratin CAM5.2, unlike SCC of the anal margin, suggesting a common cell of origin for both rectal cancer subtypes. This lends support to an idea that the mucosal lining of the rectum contains a common pluripotent endodermal stem cell, which under certain conditions (inflammation and epithelial damage) can undergo squamous differentiation to better protect the rectum from the inciting cause. This is visualised as an area of metaplasia, which can subsequently undergo dysplasia and carcinomatous change if the inciting cause is not removed. HPV has been postulated as a possible factor in inciting the dysplastic change of the squamous metaplasia. However, while there is a strong association between HPV and SCC of multiple sites including the anus, head/neck and cervix, the role in SCC of the rectum has not currently been established. There are more than 100 subtypes of HPV, with the most frequently encountered oncogenic forms being HPV 16 and 18. There are only a limited number of studies that have examined for HPV in rectal SCC, and they have utilised varying techniques for detection with discordant results. Audeau et al [18] used immunohistochemistry to examine 20 squamous lesions (squamous metaplasia, SCC, adenosquamous carcinoma), without evidence of HPV 6, 11, 16 or 18. Frizelle et al [3] and Nahas et al [16] used an in situ hybridisation technique on 6 and 5 rectal SCC specimens respectively, again without evidence of HPV deoxyribonucleic acid (DNA). However, studies by Sotlar et al [28] (1 rectal SCC), Kong et al [12] (2 rectal SCC, 1 rectal SCC in situ), Matsuda et al [29] (1 rectal SCC) and Jaworski et al [17] (2 rectal SCC in situ), all identified HPV 16 in 7 rectal squamous lesions when utilising the PCR method, which is regarded as the gold standard. This may indicate that the sensitivity of the test employed in the detection of HPV has previously masked its presence. The case presented by Sotlar et al [28] is also of particular interest, given that it reported the findings of adjacent squamous metaplasia, dysplasia, and carcinoma in sequence, with HPV 16 identified in all three components and the surrounding non-tumour affected rectal mucosa. This mirrors the pre-neoplastic to neoplastic progression well documented in HPV driven anogenital cancers. Furthermore, they identified transcriptional activity of the HPV E6/7 oncogenes critical to HPV's role in carcinogenesis. This may suggest that there are two possible pathways to the pathogenesis of colorectal SCC, HPV driven and non-HPV driven. However, while there is currently limited evidence surrounding HPV in rectal SCC, a clear association and a role in causation remains to be Given the strong association of human papilloma virus (HPV) with anal SCC, several studies have investigated its role in rectal SCC. This has produced variable results, with as many studies identifying HPV 16 in colorectal SCC specimens [12, 17, 28, 29] , as those that have failed [3, 16, 18] . Given this limited evidence, HPV infection as a risk factor for rectal SCC remains to be proven.
Pathogenesis:
Despite reports of rectal SCC since the early 20 th century, it's underlying aetiology remains unclear. While multiple theories have been postulated over this time period, its pathogenesis continues to be unravelled by assimilating the current body of evidence.
The theory of chronic inflammation leading to squa mous metaplasia and subsequent carcinoma is one of the most prominent. This idea draws upon the fact that irritation and inflammation can lead to a change in the epithelial lining. This is termed metaplasia and is known to occur in the GI tract in response to exposure to various stressors [30] . Metaplasia is the reversible change of one adult cell type into another and represents an adaptive substitution of stress-sensitive cells by a cell type better able to withstand that particular insult [31] . The postulated inciting cause for the chronic inflammation leading to metaplasia has included the risk factors mentioned above of ulcerative colitis [6, 32] , radiotherapy [14, [20] [21] [22] [23] and infection [18] . Adding support to this theory is firstly the description of squamous metaplasia in the colorectum in numerous instances. This has included sporadically [33] [34] [35] [36] , in the regenerating epithelium of chronic ulcerative colitis [15, 32] , in a rat by instillation of a chronic irritant (H2O2) and in a mouse secondary to chronic rectal prolapse [37, 38] . Secondly and of most significance, is the demonstration of an adjacent histological sequence in the rectum, from squamous metaplasia through dysplasia to carcinoma in situ ( Figure 2 ) and invasive squamous carcinoma ( Figure  3 ) [6, 7, 12, 15, 24, 35] . Drawing further upon this theory is the idea of With the above in mind, a detailed history and physical examination should be undertaken, with particular attention to the gynaecological system and anal canal. This often necessitates an examination under anaesthesia of both systems in addition to endoscopy.
The definitive diagnosis of rectal SCC is confirmed by performing a complete colonoscopy with biopsies of any abnormalities. Demonstration of the discontinuity of a lesion from the anal squamous mucosa is of great importance. Rectal SCC has been reported to have a varied endoscopic appearance dependent on the stage of disease. This can range from a small mucosal polyp (Figure 4 ), plaque or ulceration through to a large obstructing mass ( Figure 5 ) [51] . Pre-malignant lesions in the form of squamous metaplasia have also been identified by way of narrow band imaging (NBI) in addition to rectal SCC [32, 52] . One report identified an appearance of dark brown dots similar to the intraepithelial papillary capillary loops (IPCL) which herald squamous epithelium in the oesophagus using NBI [32] . There are classification systems utilising the appearance of IPCL in the oesophagus in order to identify and differentiate squamous lesions along the spectrum towards invasive carcinoma [53] . Given the possible aetiological sequence of metaplasia through to invasive carcinoma, NBI may find a role in the detection and treatment of pre-malignant lesions for those at high risk, in particular ulcerative colitis patients.
Histologically, if the diagnosis remains unclear, immunohistochemistry can aid in the characterisation of the lesion. This is particularly useful in cases of poorly differentiated tumours where the morphology and architecture provide little clue to the origin. Cytokeratins AE1/AE3, CK 5/6 (34BE12 stains CK5) and p63 stain for cells of squamous origin, assisting in the differentiation from a rectal adenocarcinoma. Cytokeratin CAM5.2 aids in the differentiation of rectal from anal, characteristically staining for rectal squamous cell or adenocarcinoma but not anal SCC. This is particularly useful for squamous carcinomas of the lower rectum [16] . Squamous cell carcinoma associated antigen is proven.
Patients with HIV have a higher incidence of HPV infection than the general population and additionally, HIV infection increases susceptibility to virally promoted cancers including Burkitt's lymphoma (Epstein barr virus), Kaposi's sarcoma (human herpes virus 8) and anogenital carcinoma (HPV). Consequently, it could be inferred that the cell mediated immune deficiency associated with HIV would predispose to rectal SCC. However, this is not borne out on review of the literature, with only two case reports of rectal SCC in the setting of HIV infection [29, 42] . Another postulated aetiology, has arisen from the finding of squamous differentiation within colorectal adenomas. Williams et al [1] found this to be present in 3 of 750 adenomas, with a separate villous adenoma containing both invasive squamous and adenocarcinoma.
Others have reported squamous metaplasia in adenomatous polyps [43] [44] [45] [46] in addition to a further case of SCC in a villous adenoma [47] . These findings may again represent the squamous differentiation of a basal colonic cell, with changes inciting development of the adenoma also possibly leading to the metaplastic change.
Diagnosis and staging
Clinical presentation and diagnosis: The pattern of presentation for patients with rectal SCC is similar to those with adenocarcinoma of the rectum. The most frequently reported symptom is per rectal bleeding, followed less commonly by altered bowel habit (constipation, diarrhoea, tenesmus), pain and weight loss [48] . The duration of symptoms can be variable, but most patients report a symptom history of weeks to months [49, 50] . Many presumed rectal SCCs are in fact an extension of an anal or gynaecological carcinoma, and consequently vigilance in diagnosis is important. Certain exclusion criteria stipulated by Williams et al [1] in 1979, remain relevant for a diagnosis of primary rectal SCC to be established: (1) metastasis to the rectum from SCC of another organ; (2) Staging involves evaluation of the primary tumour, and assessment for regional and metastatic disease. For loco-regional evaluation, as with rectal adenocarcinoma, magnetic resonance imaging (MRI) pelvis and endorectal ultrasound (ERUS) both have a role [65] . A preference for either modality is often dependent on the experience with each technique at individual institutions. In terms of utility, ERUS has advantage in determining the depth of tumour invasion, particularly with differentiating T1/2 lesions. For delineation of more advanced T3/4 tumours and to determine local nodal involvement, pelvic MRI provides improved definition [65, 66] . Recently, there has been growing interest in the use of MRI diffusion weighted imaging (DWI) as a functional modality to assess treatment response in the staging of rectal adenocarcinoma [67] . With the current shift towards definitive chemoradiotherapy in the treatment of rectal SCC, MRI is likely to find an increasingly useful role, not only for structural pretreatment staging, but more importantly to determine the functional response of the tumour post-treatment in order to guide the need for operative intervention ( Figure  6 ).
Computed tomography (CT) chest, abdomen and pelvis should be undertaken routinely in order to exclude metastatic disease. Increasingly, Fluorodeoxyglucosea serum tumour marker expressed by epidermoid tumours, including squamous carcinomas of the anal canal. Despite studies demonstrating weak evidence it may relate to nodal or relapsed disease in anal SCC, its use in diagnosis and follow-up remains controversial [54] [55] [56] . With very limited data in the setting of rectal SCC, there is currently no clear utility for SCCAg in the diagnosis or management of these patients [57] .
Staging: Accurate staging of rectal SCC is of critical importance, in the same way that it dictates prognosis and management in anal SCC and rectal adenocarcinoma. In the literature, various staging systems have been translated into use for rectal SCC, most commonly the tumour-node-metastasis (TNM) system for rectal adenocarcinoma [18, 49, [58] [59] [60] [61] [62] or the TNM system for anal SCC [16, 63, 64] . While arguments can be made for the use of either staging system, the AJCC staging for rectal carcinoma is likely to have the greatest relevance. Firstly, the tumour stage focuses on the importance of the level of invasion through the rectal wall rather than the maximal dimension of the carcinoma. Secondly, nodal involvement is likely to follow the lymphatic drainage to the mesorectum and higher echelons, in preference to the alternative routes often involved in anal carcinoma such as the inguinal basins. location of the tumour. Local excision either transanal or endoscopic, has been advocated for selected cases, with several publications reporting short-term survival without recurrence in the setting of trans-anal excision followed by chemoradiotherapy [12, 16, 48, 70, 71] . This included a T3 lesion and another with positive distal and radial margins, suggesting the chemoradiation may have played an important role in reducing local recurrence [16, 70] . With the evolution of endoscopic techniques, in particular endoscopic mucosal resection and submucosal dissection in the treatment of early rectal cancers [72] , these procedures may have a role in managing rectal SCC. Generally, the option of local excision would be limited to low risk T1 lesions, characterised as being well differentiated, without lymphovascular involvement, nodal or metastatic disease.
For most rectal SCC's, anterior resection (AR) or abdominoperineal resection (APR) has classically been performed. The choice and extent of the operation is dependent upon the tumour location and depth of invasion, occasionally requiring exenteration, with positron emission tomography fused with simultaneous CT and more recently MRI imaging, is also finding a role in the staging of rectal SCC. Firstly, it allows exclusion of a non-rectal primary SCC that has metastasised to the rectum. Secondly it defines the extent of the primary and nodal disease. Thirdly, it has utility similar to MRI DWI imaging, in assessing the functional response of the tumour by comparing pre and post-treatment scans ( Figure 7 ) [65, 68] .
Treatment
The treatment of rectal SCC has traditionally involved surgery, in some cases preceded or followed by adjuvant radiotherapy or chemotherapy (Table 1) [16, 69] . However, in the last decade, there has been increasing interest in the response of rectal SCC to definitive chemoradiotherapy, with very encouraging results ( Table  2) .
Surgery: Surgery has historically been adopted from the treatment of rectal adenocarcinoma with the operative technique, dependent upon the stage and increasing trend in the use of chemoradiation either as definitive treatment or in conjunction with surgery is emerging. There have been several prospective studies evaluating the role of chemoradiation as the primary therapy. The earlier cohorts demonstrated suboptimal outcomes, without a change in mortality or avoidance of surgery [25, 75] . However, with improvements in chemotherapy, radiotherapy and the accuracy of determining stage and response, a multitude of recent studies utilising an anal SCC based treatment regimen have reported promising results (Table 2) [3, 16, 49, 57, 61, 63, 69] . The 3 most recent case series all published in 2015, comprise 22 patients treated with definitive chemoradiotherapy. Of this grouped cohort, a CR was identified by clinical examination and/or imaging in 14 of the 22 patients [59, 63, 76] . The remaining 8 patients who demonstrated either progression of disease, a partial response or discordance between clinical and radiological findings, underwent a salvage operation. Of this group, 5 were noted to have a complete pathological response, equating to 19 of the 22 patients demonstrating a CR. Median follow up was 25 mo, with three patients suffering a recurrence, two of whom underwent a salvage operation, and one who received radiotherapy given the recurrence was outside the original field of treatment. Of these three, one succumbed to their disease at 14 mo post salvage surgery. One patient with an initial partial response and subsequent salvage operation developed metastatic disease without local relapse. The remaining 20 patients removal of involved pelvic structures. On review of the literature, APR was performed much more frequently than AR prior to the year 2000, with an equal split in the frequency of both procedures following the turn of the century (Table 1) . This is likely to reflect both the change towards sphincter preservation and avoidance of a permanent stoma in operations for rectal cancer over previous decades, in addition to a down-staging effect of chemoradiation, which is now commonplace. While the incidence of APR and a definitive stoma has been falling, in a similar manner to rectal adenocarcinoma, most patients with a low rectal SCC will require a temporary covering ileostomy given the greater risk of anastomotic leak. Furthermore, for those patients presenting with an obstructing tumour, the use of a defunctioning stoma is an attractive option, providing time to appropriately stage the patient and consider the optimal treatment, including definitive chemoradiotherapy.
Chemoradiotherapy: Following the validation of Nigro's protocol in multiple randomised controlled trials, it has now become the accepted standard treatment for anal SCC. Surgery, previously the preferred management, has subsequently been relegated to a salvage role [73, 74] . In light of this development, a trend of treating rectal SCC in the same manner has emerged.
On review of the literature, which spans from 1933 to the present, it is difficult to compare the treatment of rectal SCC, given the lack of a standardised staging system and treatment protocol. Nonetheless, an were respectively 25% vs 10% and 30% vs 13% for the chemoradiation vs conventional treatment cohorts. These differences are likely due to a combination of factors, including improvements in imaging, tumour staging and perioperative workup and patient care over time. Furthermore, there are significant limitations in the analysis and interpretation of these results, related to the inherent heterogeneity of case reports and the inconsistency in recording important prognostic variables are alive without evidence of disease [59, 63, 76] . Expanding from the above findings, when all cases reported in the literature are examined, it is obvious that patients undergoing definitive chemoradiotherapy have a far superior survival then what has been historically recorded (Table 1 compared with Table 2 ). The overall survival for the chemoradiation group was 86% compared with 48% for conventional treatment. Likewise, the local recurrence and metastatic rates Raiford et al [5] 1 -PP -1 -LR 0% 21 Catell et al [81] 1 -APR --100% (1) 42 LeBlanc et al [30] 5 -1 -APR, PR -4 -1 -LR 40% (2) 3-60 O'Brien et al [82] 2 -APR × 2 --100% (2) 12 Kron et al [83] 1 -APR -1 -M, 1 -LR 0% 5 2 Dixon et al [84] 1 -PR -NR NR -Burns et al [85] 1 -APR --100% (1) 42 Wiener et al [86] 1 -APR -M -1, LR -1 0% 12 Zirkin et al [6] 1 -TPC/APR --100% (1) 16 Hohm et al [7] 2 -APR × 2 --100% (1) 156-252 Angelchik et al [87] 1 -AR --100% (1) 18 Cabrera et al [34] 1 -APR --100% (1) 10 Minkowitz et al [24] 1 -TPC -M -1 0% 5 2 Higton et al [11] 1 -AR -NR NR -Comer et al [10] 1 -APR --100% (1) 156 Williams et al [1] 1 -APR -M -1 0% 9 Vezeridis et al [25] 4
CTx -1 APR -3 CTx -1 M -2, LR -1 0% 0-15 Lafreniere et al [48] 1 -TAE CRTx -100% (1) 24 Pigott et al [88] 1 -APR RTx -100% (1) 13 Woods et al [35] 1 -APR --0% 3 Prener et al [71] 5 -APR -4, TAE -1 RTx -1 LR -3, M -1 20% (1) 3-36 Schneider et al [70] 1 -TAE CRTx -100% (1) 6 Fazzi et al [89] 1 -Y RTx -100% (1) 72 Copur et al [90] 1 -APR CRTx M -1 NR - 2 Frizelle et al [3] 9 -NR NR NR NR -Sotlar et al [28] 1 -AR -LR -1 0% 21 Gelas et al [69] 4
RTx -2 APR x 3 CRTx -1, RTx -1 LR -1, M -2 25% (1) 4-192 Anagnostopoulos et al [91] 1 -APR CTx -100% (1) 14 Fahim et al [92] 1 -APR CTx LR -1, M -1 0% 11 2 Lam et al [93] 1 RTx AR --NR - 2 Cheng et al [15] 1 -TPC CRTx -NR -Kong et al [12] 2
CTx -1 TAE -1 CRTx -1 -50% (1) 36 Nahas et al [16] 3
CTx -1 APR, TAE CRTx -2 -100% (3) 6-192 1 Leung et al [20] 1 -S -M -1 0% - 2 Dzeletovic et al [52] 1 NR NR NR NR NR -Sameer et al [94] 1 -AR CTx -100% (1) 24 Wang et al [60] 2 -H, TAE CRTx -2 M -1 50% (1) 21, 120 Sanal et al [95] 1 CTx AR --100% (1) 12 Yeh et al [49] 1 -APR M -1 0% 7 Faidzal et al [96] 1 -AR CRTx -100% (1) 15 Wang et al [97] 1 -APR RTx -100% (1) 43 Scaringi et al [23] 1 -AR -LR -1, M -1 0% 4 Ozuner et al [14] 7 -APR -3 AR -1 TPC -1 TAE 1, H -1
Péron et al [59] 1 justifies this approach. For those cases with clear progression of disease through chemoradiation, salvage surgery should be undertaken as the next line of treatment to ensure optimal outcomes. However, in the setting of a partial response or stable disease, the pathway is less clear. It has been suggested that a more prolonged assessment, with regular EUAs even out to 6 mo, could be required for a better evaluation of tumour response. This is in consideration of the finding that multiple patients with an eventual pathological CR had clinical and radiological findings suggestive of persistent disease in the early post chemoradiation stage [16] . This is also in keeping with the accepted management of anal SCC, where a delayed tumour response may continue for 6 mo after the completion of chemoradiation [63] . In the grouped chemoradiation cohort (Table 2) , a CR on pathology was identified in 57% of patients, suggesting that time may have played a role in assessing clinical and radiological response. As with rectal and anal cancer, this is likely to remain a contentious area until a more effective means including stage and grade. Despite these limitations, the treatment itself almost certainly accounts for a significant component of the dramatically improved local control and survival.
As with rectal and anal cancer, one of the most pertinent issues with definitive chemoradiation, is deter mining treatment response, which currently can only be confirmed on histopathology [73, 77] . In the studies to date on rectal SCC, response to chemoradiotherapy has been assessed variably, from 6-8 wk up to 6 mo after the conclusion of treatment. This generally involves a combination of a clinical assessment, by way of a repeat EUA/proctoscopy + biopsy, and an imaging assessment in the form of MRI ± PET/CT ± ERUS [49, 58, 60, 61] . For patients with a complete clinical and radiological response, follow up and surveillance is performed at regular intervals with reducing frequency out to five years, generally 3 monthly for the first two years, and 6 monthly out to five years. While this is certainly labour and resource intensive with consequent costs, the improved overall and stoma free survival certainly 
Follow up (mo) 5FU/MMC Other
Vezeridis et al [25] 1 -1 40 ---LR -1 0% 15 1 Schneider et al [70] 1 1 -30 ----NR -Kulayat et al [13] 1 1 -40 -TPC 100% -100% (1) 48 Martinez-Gonzalez et al [75] 1 -1 46 -AR 0% -100% (1) 18 Gelas et al [69] 2 -2 Y -AR -2 0% -100 % (2) 6-24 Theodosopoulos et al [98] 1 1 -20 -APR 0% M -1 100% (1) 18 Pikarsky et al [9] 1 1 -60 1 ---100% (1) 84 Nahas et al [16] [29] 1 -1 59.4 -APR 0% LR -1, M -1 0% 24 Brammer et al [99] 1 [102] 1 -1 Y -AR 0% -100% (1) -Ferreira et al [64] 1 1 -52 1 ---100% (1) 40 Choi et al [42] 1 advances in treatment as this disease is better defined, gives hope for improved patient outcomes. While SCC of the rectum is a rare entity, there is an increasing body of evidence that is improving our understanding of its underlying aetiology. Despite the literature lacking uniformity in the staging and management of rectal SCC, it is hard to ignore the impressive improvements in overall survival and sphincter preservation by way of chemoradiotherapy as the primary modality of treatment. This holds much promise for the future, and certainly lays the foundation for further investigation into determining the optimal treatment regimen.
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Background
A summary of the current body of knowledge surrounding the pathogenesis, presentation, diagnosis, staging and management of rectal squamous cell carcinoma (SCC), with a focus on the changing treatment paradigm and consequent improved patient outcomes.
Research frontiers
While the underlying pathogenesis of rectal SCC is yet to be fully defined, a possible role for human papilloma virus presents an avenue for future investigation. Furthermore, the identification of premalignant lesions in the development of rectal SCC raises the possibility of surveillance in high risk patients. The use of magnetic resonance imaging (MRI) and positron emission tomography (PET) has an emerging role not only in diagnosis and staging, but also importantly as a functional modality to determine response to chemoradiotherapy. This role has arisen from the recent shift in the primary treatment of rectal SCC to chemoradiotherapy, accompanied by a dramatic improvement in overall survival.
Innovations and breakthroughs
Assimilation of the current body of evidence lends support to the presence of premalignant lesions and a metaplasiadysplasiacarcinoma sequence in the development of rectal SCC. Staging for rectal SCC fits more appropriately with the tumournodemetastasis (TNM) criteria for rectal adenocarcinoma than anal SCC. MRI and PET are finding an increasing role in diagnosis, staging and assessment of response to treatment in rectal SCC. Chemoradiotherapy offers improved patient outcomes without the associated morbidity of surgery. Improved markers of complete response will assist in determining the need for salvage treatment in this patient cohort.
Applications
Consideration should be given to screening for premalignant lesions in high risk individuals. Uniform staging utilising the current TNM criteria for rectal adenocarcinoma should be encouraged. PET and MRI should be incorporated into the evaluation of patients, pre and post treatment. Definitive chemoradiotherapy offers improved patient outcomes without the associated morbidity of surgery. While treatment must be individualised and based on patient and tumour factors, chemoradiation should form the basis of primary management.
Terminology
Complete response refers to the resolution of tumour following treatment with chemoradiotherapy. While radiological investigations and clinical examination can act as surrogate markers, a true complete response can currently only be determined post resection and pathological examination.
Peer-review
The review article described the background, diagnosis and staging, treatment, of determining response is available [78] . Despite the encouraging results of chemoradiotherapy, currently a set treatment protocol is yet to be established. It appears that 5FU based chemotherapy combined with high dose external beam radiotherapy may be efficacious. However, while these trends are grossly evident from the literature, there is a need for further research in order to determine the most effective regimen to optimise patient outcomes.
It is unlikely that a randomised trial comparing surgery and chemoradiotherapy will ever be conducted for this rare cancer. Given the current knowledge base, it may be reasonable to suggest that primary treatment should be chemoradiotherapy, with surgery reserved as a salvage option. The suggested regimen would be a total dose of 50.4 to 54 Gy external beam radiation in 1.8 Gy per fraction, given concurrently with 5FU and mitomycin C.
Future options: Over recent years, there has been an increasing use of molecular targeted therapies in solid and haematological malignancies [79] . Furthermore, immunotherapy in the form of tumour vaccines, adoptive T cell therapy and immune checkpoint inhibitors has become a major focus for research in the treatment of cancer, with translated clinical success in specific tumour types [80] . While there is currently no literature on these modalities in rectal SCC, the early results in other tumours holds promise for a possible role in future treatment, particularly in the cohort of patients with persistent, recurrent or metastatic rectal SCC.
Prognosis
The most important predictor of survival in all cancers is the stage of disease. This is based upon three factors; the size of the primary tumour and depth of invasion (T stage); the location and number of lymph nodes involved (N stage); and the presence or absence of metastasis (M stage). Rectal SCC follows the same route of lymphatic spread for involvement of lymph nodes as rectal adenocarcinoma. Additionally, it has a similar pattern of metastasis with the liver, lung and bones most commonly affected [66] . While the majority of patients with rectal SCC present with locoregional disease (stage I-III, 82.1%), they are associated with a poorer overall survival when compared stage for stage with adenocarcinoma. From review of the population study by the NCI, the overall 5-year survival for rectal SCC was found to be 48.9% compared with 62.1% for adenocarcinoma. When localised, the 5 years OS was 73.7% (91.8% -adenocarcinoma), with 31.3% (65.8%) for regional and 20.8% (8.8%) for metastatic [2] . While the above figures and those from older studies report a poor prognosis for patients with rectal SCC, recent studies employing a new treatment paradigm, demonstrate a significantly improved overall survival. The possibility of further
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